Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?

For biotech and pharma insiders, Vertex's blockbuster move on Crinetics is more than a single deal—it's a valuation benchmark that recalibrates the entire endocrinology acquisition landscape. Viking Therapeutics, armed with a parallel strategy of subcutaneous and oral incretin assets plus a novel-mechanism early-stage compound, suddenly finds itself under a microscope. The clinical data and trial design differentiation these candidates bring could dictate not just Viking's future but the next wave of obesity's therapeutic evolution.

Vertex Pharmaceuticals' landmark $10 billion cash acquisition of Crinetics Pharmaceuticals—the largest in Vertex's history—signals an accelerating biopharma land grab for next-generation metabolic therapies. While the deal has yet to close, it instantly rewires the endocrinology landscape and underscores the premium that deep-pocketed drugmakers are willing to pay for late-stage obesity and related pipeline assets. The immediate beneficiary of the deal's ripple effect is Viking Therapeutics, a clinical-stage biotech with a portfolio of weight-loss candidates that align tightly with the escalating industry hunger for non-incretin, differentiated mechanisms in a market projected to reach $190 billion by 2035.

“

adults are overweight or obese, according to the CDC, driving a therapeutic market that more than doubled from $79 billion in 2025 to an estimated $190 billion by 2035.

The Crinetics acquisition hands Vertex a suite of potential best-in-class endocrine candidates, most notably paltusotine, a once-daily oral somatostatin receptor agonist for acromegaly and carcinoid syndrome, alongside early-stage programs in congenital hyperinsulinism and other rare conditions. The move is a clear strategic pivot for Vertex, which built its empire on cystic fibrosis but now faces patent cliffs and the imperative to diversify into high-growth, chronic-disease markets. By paying $10 billion—roughly 2.5 times Crinetics' unaffected valuation—Vertex validates the thesis that obesity and metabolic assets command outsized premiums in today's deal environment.

That thesis centers on the staggering unmet need: over 70% of U.S. adults are overweight or obese, according to the CDC, driving a therapeutic market that more than doubled from $79 billion in 2025 to an estimated $190 billion by 2035. Despite the success of GLP-1 agonists from Novo Nordisk and Eli Lilly, the market remains underserved, with room for agents that offer improved tolerability, oral convenience, and additive efficacy. Viking Therapeutics' pipeline is uniquely positioned to address these gaps. Its lead candidate, VK2735, is a subcutaneous dual GLP-1/GIP receptor agonist in Phase 3 development, with an oral formulation expected to enter late-stage trials by year-end 2026. A third asset, VK3019, is a next-generation weight-loss candidate that just started Phase 1 studies. This three-pronged approach covers injectable, oral, and novel-mechanism modalities, exactly the kind of broad, de-risked portfolio that large acquirers covet.